Last $1.60 USD
Change Today +0.05 / 3.23%
Volume 32.2K
VRML On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $3.83
52 Week Low
10/15/14 - $1.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women’s health. The company’s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.

26 Employees
Last Reported Date: 03/31/14
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $184.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

vermillion inc (VRML) Key Developments

Vermillion Mulls Acquisitions

Vermillion, Inc. (NasdaqCM:VRML) has filed a shelf registration in the amount of $50.00 million. Vermillion, Inc. intends to use the net proceeds for general corporate purposes, including working capital, for further research and development and ongoing sales and marketing expenses, and, potentially, capital expenditures and licensing of additional technologies and to acquire or invest in complimentary businesses, technologies, product candidates or other intellectual property.

Vermillion, Inc. Appoints Holly B. Bauzon as Vice President of Sales and Managed Markets

Vermillion, Inc. has appointed Holly B. Bauzon as Vice President of Sales and Managed Markets. Ms. Bauzon has more than 20 years of healthcare experience, most recently with PerkinElmer, Inc., where she held the position of Director, Lab Services Sales and Managed Markets. Prior to her seven year tenure at PerkinElmer, Ms. Bauzon held commercial management and payer relations positions at PolyMedica Corporation, National Diabetic Pharmacies, Inc. and Byram Healthcare, Inc.

Vermillion, Inc. Appoints Dr. Judith K. Wolf as Chief Medical Officer, Effective September 15, 2014

Vermillion, Inc. appointed Dr. Judith K. Wolf to the new position of Chief Medical Officer, effective September 15, 2014. Dr. Wolf is a published and active professional in the field of gynecologic cancer. She currently serves as the Division Chief of Surgical Oncology and Vice Chair of the Department of Oncology Services at the Banner MD Anderson Cancer Center in Arizona.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $1.60 USD +0.05

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.14 USD 0.00
Health Discovery Corp $0.02 USD -0.0004
Imperial Innovations Group PLC 463.00 GBp +10.50
MDxHealth €3.77 EUR +0.099
Miraculins Inc C$0.16 CAD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.8x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at